{"id":4417,"date":"2019-03-26T05:11:06","date_gmt":"2019-03-26T05:11:06","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4417"},"modified":"2019-11-12T15:29:11","modified_gmt":"2019-11-12T15:29:11","slug":"un-estudio-sobre-el-plx8394-como-farmaco-en-monoterapia-en-pacientes-con-tumores-solidos-avanzados-inoperables","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/es\/study_trials\/a-study-of-plx8394-as-a-single-agent-in-patients-with-advanced-unresectable-solid-tumors\/","title":{"rendered":"Estudio sobre el PLX8394 como f\u00e1rmaco en monoterapia en pacientes con tumores s\u00f3lidos avanzados e inoperables"},"content":{"rendered":"<p><strong>Objetivo del estudio:<\/strong>&nbsp; El objetivo de este estudio de investigaci\u00f3n cl\u00ednica es averiguar c\u00f3mo puede afectar el PLX8394 a las c\u00e9lulas cancerosas que presentan mutaciones en el gen BRAF. El PLX8394 est\u00e1 dise\u00f1ado para bloquear las mutaciones en el gen BRAF. Estas mutaciones pueden provocar c\u00e1ncer y el crecimiento de las c\u00e9lulas cancerosas.\u00a0 Al bloquear estas mutaciones, el f\u00e1rmaco podr\u00eda destruir las c\u00e9lulas cancerosas que presentan la mutaci\u00f3n y\/o impedir que el tumor siga creciendo.<\/p>\n<p><strong>Patrocinador:<\/strong>&nbsp; Plexxikon<\/p>\n<p><strong>Datos de contacto del ensayo:<\/strong>&nbsp; Divya Sakamuri; 1-713-745-3296; dsakamuri@mdanderson.org o Filip Janku; 713-563-1930; FJanku@mdanderson.org<\/p>\n<p><strong>Participaci\u00f3n solicitada del paciente:<\/strong>&nbsp; Pacientes con ECD mayores de 18 a\u00f1os.<\/p>\n<p><strong>Centros conocidos que admiten a pacientes con ECD en el ensayo:<\/strong>&nbsp; MD Anderson, Houston, Texas<\/p>\n<p><strong>Identificador de ClinicalTrials.gov:<\/strong>&nbsp; NCT02428712<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; The goal of this clinical research study is to learn how PLX8394 may affect cancer cells with mutations in the gene BRAF.&nbsp; PLX8394 is designed to block mutations [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4417","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials\/4417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/media?parent=4417"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/es\/wp-json\/wp\/v2\/study_trials_cat?post=4417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}